Key facts
- It has raised $372.8M across 4 recorded rounds; the latest was Later Stage VC (Series D) ($159.8M) in Sep 2022.
- RayzeBio has filed 4 Form Ds with the SEC since 2020, most recently Sep 2022 ($167.9M sold to 18 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for RayzeBio
Create free account
No card required
Funding rounds
4 roundsSep 2022Later Stage VC (Series D)$159.8M▮
Jun 2021Later Stage VC (Series C)$108.0M▮
Nov 2020Early Stage VC (Series B)$105.0M▮
About RayzeBio
- Industry
- Drug Discovery
PA Mark — not yet priced
RayzeBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in RayzeBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on RayzeBio in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.